Unknown

Dataset Information

0

TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection.

ABSTRACT: Dysregulated Toll-like receptor (TLR)-4 activation is involved in acute systemic sepsis, chronic inflammatory diseases, such as atherosclerosis and diabetes, and in viral infections, such as influenza infection. Thus, therapeutic control of the TLR4 signalling pathway is of major interest. Here we tested the activity of the small-molecule synthetic TLR4 antagonist, FP7, in vitro on human monocytes and monocyte-derived dendritic cells (DCs) and in vivo during influenza virus infection of mice. Our results indicate that FP7 antagonized the secretion of proinflammatory cytokines (IL-6, IL-8, and MIP-1?) by monocytes and DCs (IC50?

SUBMITTER: Perrin-Cocon L 

PROVIDER: S-EPMC5247753 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection.

Perrin-Cocon Laure L   Aublin-Gex Anne A   Sestito Stefania E SE   Shirey Kari Ann KA   Patel Mira C MC   André Patrice P   Blanco Jorge C JC   Vogel Stefanie N SN   Peri Francesco F   Lotteau Vincent V  

Scientific reports 20170120

Dysregulated Toll-like receptor (TLR)-4 activation is involved in acute systemic sepsis, chronic inflammatory diseases, such as atherosclerosis and diabetes, and in viral infections, such as influenza infection. Thus, therapeutic control of the TLR4 signalling pathway is of major interest. Here we tested the activity of the small-molecule synthetic TLR4 antagonist, FP7, in vitro on human monocytes and monocyte-derived dendritic cells (DCs) and in vivo during influenza virus infection of mice. Ou  ...[more]

Similar Datasets

Unknown The TLR4 antagonist Eritoran protects mice from lethal influenza infection.
| S-EPMC3725830 | biostudies-literature
Unknown A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression.
| S-EPMC2118317 | biostudies-literature
Unknown Glycolytic reprogramming of macrophages activated by NOD1 and TLR4 agonists: No association with proinflammatory cytokine production in normoxia.
| S-EPMC7062164 | biostudies-literature
Unknown The synthetic glycolipid-based TLR4 antagonist FP7 negatively regulates in vitro and in vivo haematopoietic and non-haematopoietic vascular TLR4 signalling.
| S-EPMC6830872 | biostudies-literature
Unknown Human resistin protects against endotoxic shock by blocking LPS-TLR4 interaction.
| S-EPMC5715788 | biostudies-literature
Transcriptomics Transcription profiling of human dendritic monocytes treated with LPS (lipopolysaccharide) or CyP (Cyanobacterial Product) reveals cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression
2007-10-26 | E-GEOD-4748 | biostudies-arrayexpress
Unknown Heparanase-2 protects from LPS-mediated endothelial injury by inhibiting TLR4 signalling.
| S-EPMC6753096 | biostudies-literature
Unknown Stem Cell-Induced Inflammation in Cholesteatoma is Inhibited by the TLR4 Antagonist LPS-RS.
| S-EPMC7017370 | biostudies-literature
Unknown Cell-Intrinsic Glycogen Metabolism Supports Early Glycolytic Reprogramming Required for Dendritic Cell Immune Responses.
| S-EPMC5657596 | biostudies-literature
Unknown Ponatinib Protects Mice From Lethal Influenza Infection by Suppressing Cytokine Storm.
| S-EPMC6598400 | biostudies-literature